Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Topical Alicaforsen Enema in Subjects With Active, Chronic, Antibiotic Refractory Primary Idiopathic Pouchitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Alicaforsen (Primary)
- Indications Pouchitis
- Focus Registrational; Therapeutic Use
- Sponsors Atlantic Healthcare; Atlantic Pharmaceuticals
- 27 Oct 2021 Results assessing effect of alicaforsen enema on endoscopic remission and stool frequency presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021
- 31 Jul 2019 Primary endpoint has not been met. (Proportion of patients with a reduction in relative stool frequency), according to an Atlantic Healthcare media release.
- 31 Jul 2019 Primary endpoint has not been met. (Proportion of patients with endoscopic remission), according to an Atlantic Healthcare media release.